🆕Our Aug issue is live! 📊Articles: #bladdercancer #Breastcancer #urothelialcarcinoma #NSCLC 📉Trials: HORIZON-Breast01, SERENA-6, SUPREMO, JCOG1403, BOND-003, PICC-2, PERISCOPE II 🎨Cover: Advancing oncology education in LMIC African settings 🖱️https://www.thelancet.com/issue/S1470-2045(26)X2007-1

🚨Online now: Efficacy and safety of dabrafenib plus trametinib in adults with differentiated #thyroidcancer: a randomised, double-blind, placebo-controlled, phase 3 trial 📊Read here: thelancet.com/journals/lan... 📝Linked comment: thelancet.com/journals/lan...

🚨Our July podcast! Hans Merks on European guidelines for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma 🎧Listen & subscribe: Spotify open.spotify.com/show/3JOj0Cl... Apple podcasts.apple.com/us/podcast/t... 📕Read here: www.thelancet.com/pdfs/journal...

Ready to share your #ClinicalOncology research with millions globally? Explore our author resources for a seamless submission process, and start your publication journey with us today: hubs.li/Q04mkDC40

The Lancet Oncology@thelancetoncol.bsky.social · last mo.

Behind every paper is a community. To every author who trusted us with their research and every peer reviewer who gave their time and expertise—thank you! Together, we are advancing the best science for better lives. Learn about our peer review process: hubs.li/Q04mCzF70

Behind every paper is a community. To every author who trusted us with their research and every peer reviewer who gave their time and expertise—thank you! Together, we are advancing the best science for better lives. Learn about our peer review process: hubs.li/Q04mCzF70

The Lancet Oncology@thelancetoncol.bsky.social · last mo.

We are an internationally trusted journal for clinical and global #oncology, with a:   Journal Impact Factor of 33·7  Scopus CiteScore of 42·0  Explore our high impact and global reach: hubs.li/Q04k_cRQ0 #ClinicalOncology #MedicalResearch #ClinicalTrials

We are an internationally trusted journal for clinical and global #oncology, with a:   Journal Impact Factor of 33·7  Scopus CiteScore of 42·0  Explore our high impact and global reach: hubs.li/Q04k_cRQ0 #ClinicalOncology #MedicalResearch #ClinicalTrials

✏️Our July Editorial: Historic moments "Attending large scientific conferences can be an endurance test....but occasionally, it becomes apparent that the conference in question is different, that something historic has happened." Read here: thelancet.com/journals/lan...

The Lancet Oncology@thelancetoncol.bsky.social · last mo.

🆕Our July issue is live! 📊Articles: #NSCLC #Breastcancer #prostatecancer #glioblastoma 📉Trials: AENEAS2, SUBITO, EORTC 22922/10925, ARTO, PRIMARY2, CAIRO6, & INTRAGO-II 🎨Cover: Meta-analysis on AEs of CD3 T cell-engaging bispecific abs Read here: thelancet.com/issue/S1470-...

📢 New @thelancetoncol.bsky.social publication insights from EORTC trial 22922/10925 focusing on an unplanned subset analysis of patients with node-negative (pN0) breast cancer with centrally or medially located tumours. 🎥 Watch video & learn more: www.eortc.org/blog/2026/05... #EORTCbreast

🆕Our July issue is live! 📊Articles: #NSCLC #Breastcancer #prostatecancer #glioblastoma 📉Trials: AENEAS2, SUBITO, EORTC 22922/10925, ARTO, PRIMARY2, CAIRO6, & INTRAGO-II 🎨Cover: Meta-analysis on AEs of CD3 T cell-engaging bispecific abs Read here: thelancet.com/issue/S1470-...

🆕Our June issue is live! 📊Articles: #prostatecancer, #breastcancer, #kidneycancer, #RCC, #glioma 📉Including trials: CAN-2409, FAST-Forward, OCLURANDOM, FASTRACK, & UNITED ✏️Perspective: Equity in Germany's National Lung Cancer Screening Read here: thelancet.com/issue/S1470-...

🚨 Attend the #ASCO26 session today: A Workforce Crisis—A Lancet Oncology Commission May 31, 2026, 4:30 PM-5:45 PM CDT at #ASCO 📕Booklet available at outside session and online 🖱️http://thelancet.com/commissions-do/cancer-workforce 📽️ youtu.be/VYr2Bjmxyhg

Cancer workforce—a global crisis

YouTube video by The Lancet

youtu.be

Heading to #ASCO26? Reach out to Dr David Collingridge, Editor-in-Chief at @thelancetoncol.bsky.social, attending #ASCO26 🗓️ Attend the Global Oncology: A Workforce Crisis—A Lancet Oncology Commission session May 31, 2026, 4:30 PM-5:45 PM CDT #cancerworkforce meetings.asco.org/meetings/202...

Heading to #ESTRO26? Attend our Top Clinical Trials session, May 17 Reach out to Cheryl Lai, Deputy Editor at @thelancetoncol.bsky.social, attending #ESTRO and say hello!

🎉Proud to share our first online article by @nathaliealbert.bsky.social & colleagues that was presented at #NMN2026 @nmnsymposium.bsky.social www.thelancet.com/action/showF...

Imaging-based classification of blood–brain barrier disruption in glioblastoma for patient selection in clinical trials: the NMN-BBB score

The blood–brain barrier (BBB) limits the activity of novel treatments, such as pharmacotherapies and targeted radionuclide therapies in glioblastoma. Selection of patients with extensive tumoural BBB ...

thelancet.com

@thelancetoncol.bsky.social news desk: www.thelancet.com/journals/lan...

US Senate Bill aims to boost cancer trial enrolment and equity

One in five cancer clinical trials in the USA fail due to insufficient patient enrolment, according to a report from the American Cancer Society Cancer Action Network. Recruitment challenges are pushi...

thelancet.com

🎧Our May podcast: Cheryl Lai is joined by Fred Saad (Montreal) to discuss pain and HRQOL outcomes from the ARANOTE trial in metastatic hormone-sensitive prostate cancer 📊Article: www.thelancet.com/journals/lan... Spotify: open.spotify.com/episode/1EGt... Apple: podcasts.apple.com/us/podcast/t...

The Lancet Oncology@thelancetoncol.bsky.social · 3mo ago

🆕Our May issue is live! 📊Articles: #breastcancer, #prostatecancer, and #softtissuesarcoma 📑Reviews: Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer from the EORTC–ESTRO OligoCare consortium Read here: thelancet.com/issue/S1470-...

Join IARCWHO for the #IARC60 conference in Lyon, France, May 19-21. Learn from your peers from around the world how you can improve cancer prevention in your setting. Register: iarc2026conf.iarc.who.int/en/registrat...

🆕Our May issue is live! 📊Articles: #breastcancer, #prostatecancer, and #softtissuesarcoma 📑Reviews: Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer from the EORTC–ESTRO OligoCare consortium Read here: thelancet.com/issue/S1470-...

Cancer prevention isn’t the same in every country, but every local breakthrough advances global progress. Join IARCWHO for the #IARC60 conference. Learn from your peers from around the world how you can improve cancer prevention in your setting. Register: iarc2026conf.iarc.who.int/en/registrat...

🆕 Introducing The Lancet Regional Health – Eastern Mediterranean, a new #goldopenaccess journal promoting the advancement of clinical practice and health policy in the Eastern Mediterranean. Discover the new addition to The Lancet Group at: spkl.io/63328AFIyw #medsky

This month's podcast: James Nagarajah on [177Lu]-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study 🎧 Listen & subscribe! Spotify: open.spotify.com/show/3JOj0Cl... Apple: podcasts.apple.com/us/podcast/t...

The Lancet Oncology@thelancetoncol.bsky.social · 4mo ago

🆕Our April issue is live! 📊Articles: #NSCLC, #bladdercancer, #melanoma, #prostatecancer, #breastcancer 📰Reviews: A PSOGI–ESGO–ISSPP Lyon consensus & OPTIMISE-AR recommendations for visualising PROs Cover: Spaceflight as a cancer research catalyst www.thelancet.com/issue/S1470-...

✏️Our Editorial: The promise of telesurgery in oncology thelancet.com/journals/lan...

The Lancet Oncology@thelancetoncol.bsky.social · 4mo ago

🆕Our April issue is live! 📊Articles: #NSCLC, #bladdercancer, #melanoma, #prostatecancer, #breastcancer 📰Reviews: A PSOGI–ESGO–ISSPP Lyon consensus & OPTIMISE-AR recommendations for visualising PROs Cover: Spaceflight as a cancer research catalyst www.thelancet.com/issue/S1470-...

🆕Our April issue is live! 📊Articles: #NSCLC, #bladdercancer, #melanoma, #prostatecancer, #breastcancer 📰Reviews: A PSOGI–ESGO–ISSPP Lyon consensus & OPTIMISE-AR recommendations for visualising PROs Cover: Spaceflight as a cancer research catalyst www.thelancet.com/issue/S1470-...

🔴Online now: UK NICE 2026 guideline for the diagnosis and management of kidney cancer Read here: thelancet.com/journals/lan...

NICE 2026 guideline for the diagnosis and management of kidney cancer

Kidney cancer is the sixth most common cancer in adults in the UK, with approximately 13 900 new cases every year.1 Kidney cancer incidence rates have almost doubled since the 1990s and are projected ...

thelancet.com

🎧NEW podcast Our editor-in-chief, Ali Landman talked with Cheryl Lai, deputy editor of @thelancetoncol.bsky.social about our journal, its scope, the team. She also shared her takeaways from the European Congress of Radiology #ECR. #RadSky

Ali Landman on the European Congress of Radiology 2026 - The Lancet Oncology in conversation with

Join us for this special episode where Deputy Editor Cheryl Lai speaks with Ali Landman, Editor-in-Chief of The Lancet Medical Imaging & Theranostics, about the scope and vision of the new journal...

buzzsprout.com

@thelancetoncol.bsky.social are proud to be media partners of #IARC@60 Conference #IARCWHO has selected the successful authors from the ~1300 abstracts submitted from all over the world. Register here: iarc2026conf.iarc.who.int/en/registrat...

In our March Editorial, we discuss England's National Cancer Plan, launched on Feb 4. The plan sets out ambitious targets, but will these be met? Read England's National Cancer Plan: hollow promises? here:🖱️https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00077-X/fulltext#f10

The Lancet Oncology@thelancetoncol.bsky.social · 5mo ago

🆕Our March issue is live! 📊Articles: #prostatecancer, #breastcancer, #melanoma, and #brachytherapy 📰Reviews: #ESTRO concensus on RT for more efficacious novel anticancer drugs + a expert consensus on oligometastatic pancreatic cancer www.thelancet.com/issue/S1470-...

🎧 Our March podcast: We talk to Dylan Graetz and Erica Kaye @stjuderesearch.bsky.social about qualitative research in oncology thelancet.com/multimedia/p... Follow In Conversation With Spotify: open.spotify.com/show/3JOj0Cl... Apple: podcasts.apple.com/us/podcast/t...

🆕Our March issue is live! 📊Articles: #prostatecancer, #breastcancer, #melanoma, and #brachytherapy 📰Reviews: #ESTRO concensus on RT for more efficacious novel anticancer drugs + a expert consensus on oligometastatic pancreatic cancer www.thelancet.com/issue/S1470-...

A clinical trial from @thelancetoncol.bsky.social explores whether advanced PET imaging improves outcomes over standard MRI for guiding re-irradiation in recurrent glioblastoma. It aligns with our journal's focus on how imaging influence treatment & patient lives 🔓https://bit.ly/thelancet-lanonc-642